Synthetic surfactin analogues have improved anti-PEDV properties

Yuan, Lvfeng; Zhang, Shuai; Peng, Jie; Li, Yuchen; Yang, Qian

doi:10.1371/journal.pone.0215227

Cited by 45 publications

(26 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mixture of surfactin and fengycin from B. subtilis fmbj was found to be able to inactivate Pseudorabies Virus, Porcine Parvovirus, Newcastle Disease Virus and Infectious Bursal Disease Virus in vitro as well as to inhibit the infection and replication processes of Newcastle Disease Virus and Infectious Bursal Disease Virus in porcine kidney and chicken embryo fibroblasts cell lines [ 135 ]. More recently, similar results were also described for other lipopeptide mixtures and surfactin analogues against Newcastle Disease Virus and Porcine epidemic diarrhea virus, respectively, corroborating the therapeutic potential of BSs for the development of new antiviral drugs [ 56 , 136 ].…”

Section: Antiviral Activitysupporting

confidence: 69%

Recent Advances in Biomedical, Therapeutic and Pharmaceutical Applications of Microbial Surfactants

et al. 2021

View full text Add to dashboard Cite

The spread of antimicrobial-resistant pathogens typically existing in biofilm formation and the recent COVID-19 pandemic, although unrelated phenomena, have demonstrated the urgent need for methods to combat such increasing threats. New avenues of research for natural molecules with desirable properties to alleviate this situation have, therefore, been expanding. Biosurfactants comprise a group of unique and varied amphiphilic molecules of microbial origin capable of interacting with lipidic membranes/components of microorganisms and altering their physicochemical properties. These features have encouraged closer investigations of these microbial metabolites as new pharmaceutics with potential applications in clinical, hygiene and therapeutic fields. Mounting evidence has indicated that biosurfactants have antimicrobial, antibiofilm, antiviral, immunomodulatory and antiproliferative activities that are exploitable in new anticancer treatments and wound healing applications. Some biosurfactants have already been approved for use in clinical, food and environmental fields, while others are currently under investigation and development as antimicrobials or adjuvants to antibiotics for microbial suppression and biofilm eradication strategies. Moreover, due to the COVID-19 pandemic, biosurfactants are now being explored as an alternative to current products or procedures for effective cleaning and handwash formulations, antiviral plastic and fabric surface coating agents for shields and masks. In addition, biosurfactants have shown promise as drug delivery systems and in the medicinal relief of symptoms associated with SARS-CoV-2 acute respiratory distress syndrome.

show abstract

Section: Antiviral Activitysupporting

confidence: 69%

Recent Advances in Biomedical, Therapeutic and Pharmaceutical Applications of Microbial Surfactants

et al. 2021

View full text Add to dashboard Cite

show abstract

“…To overcome these problems, futures studies should use higher doses or more effective delivery methods, such as intubation or the inhalation of an aerosolized surfactin. Alternatively, several surfactin derivatives exist that enhance its viricidal activity and decrease its hemolytic activity (13,14,27). Using a derivative with higher activity and specificity may compensate for inefficient delivery or dose restriction.…”

Section: Discussionmentioning

confidence: 99%

Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity

Johnson

Hage

Kalveram

et al. 2019

J Virol

View full text Add to dashboard Cite

Enteric viruses exploit bacterial components, including lipopolysaccharides (LPS) and peptidoglycan (PG), to facilitate infection in humans. Because of their origin in the bat enteric system, we wondered if severe acute respiratory syndrome coronavirus (SARS-CoV) or Middle East respiratory syndrome CoV (MERS-CoV) also use bacterial components to modulate infectivity. To test this question, we incubated CoVs with LPS and PG and evaluated infectivity, finding no change following LPS treatment. However, PG from Bacillus subtilis reduced infection Ͼ10,000-fold, while PG from other bacterial species failed to recapitulate this. Treatment with an alcohol solvent transferred inhibitory activity to the wash, and mass spectrometry revealed surfactin, a cyclic lipopeptide antibiotic, as the inhibitory compound. This antibiotic had robust dose-and temperature-dependent inhibition of CoV infectivity. Mechanistic studies indicated that surfactin disrupts CoV virion integrity, and surfactin treatment of the virus inoculum ablated infection in vivo. Finally, similar cyclic lipopeptides had no effect on CoV infectivity, and the inhibitory effect of surfactin extended broadly to enveloped viruses, including influenza, Ebola, Zika, Nipah, chikungunya, Una, Mayaro, Dugbe, and Crimean-Congo hemorrhagic fever viruses. Overall, our results indicate that peptidoglycan-associated surfactin has broad viricidal activity and suggest that bacteria by-products may negatively modulate virus infection. IMPORTANCE In this article, we consider a role for bacteria in shaping coronavirus infection. Taking cues from studies of enteric viruses, we initially investigated how bacterial surface components might improve CoV infection. Instead, we found that peptidoglycan-associated surfactin is a potent viricidal compound that disrupts virion integrity with broad activity against enveloped viruses. Our results indicate that interactions with commensal bacterial may improve or disrupt viral infections, highlighting the importance of understanding these microbial interactions and their implications for viral pathogenesis and treatment.

show abstract

“…ASFv is genetically distinct from other swine viral pathogens and is the only member of the Asfarviridae family [ 34 ]. A particularly unique feature of ASFv particles is that they have a complex structure that includes two distinct layers of lipid bilayer coating [ 35 ] as opposed to the more conventional one layer in most other membrane-enveloped viruses such as PEDv [ 36 , 37 ]. Thus, while MCFA and GML are known to inhibit a wide range of membrane-enveloped viruses, focused testing against ASFv and its more complex, double-membrane structure is warranted to evaluate possible antiviral activity and rank potency among different MCFA and GML candidates.…”

Section: Resultsmentioning

confidence: 99%

Inhibition of African swine fever virus in liquid and feed by medium-chain fatty acids and glycerol monolaurate

Jackman

Հակոբյան

Zakaryan

et al. 2020

J Animal Sci Biotechnol

View full text Add to dashboard Cite

Background The ongoing African swine fever virus (ASFv) epidemic has had a major impact on pig production globally and biosecurity efforts to curb ASFv infectivity and transmission are a high priority. It has been recently identified that feed and feed ingredients, along with drinking water, can serve as transmission vehicles and might facilitate transboundary spread of ASFv. Thus, it is important to test the antiviral activity of regulatory compatible, antiviral feed additives that might inhibit ASFv infectivity in feed. One promising group of feed additive candidates includes medium-chain fatty acids (MCFA) and monoglyceride derivatives, which are known to disrupt the lipid membrane surrounding certain enveloped viruses and bacteria. Results The antiviral activities of selected MCFA, namely caprylic, capric, and lauric acids, and a related monoglyceride, glycerol monolaurate (GML), to inhibit ASFv in liquid and feed conditions were investigated and suitable compounds and inclusion rates were identified that might be useful for mitigating ASFv in feed environments. Antiviral assays showed that all tested MCFA and GML inhibit ASFv. GML was more potent than MCFA because it worked at a lower concentration and inhibited ASFv due to direct virucidal activity along with one or more other antiviral mechanisms. Dose-dependent feed experiments further showed that sufficiently high GML doses can significantly reduce ASFv infectivity in feed in a linear manner in periods as short as 30 min, as determined by infectious viral titer measurements. Enzyme-linked immunosorbent assay (ELISA) experiments revealed that GML treatment also hinders antibody recognition of the membrane-associated ASFv p72 structural protein, which likely relates to protein conformational changes arising from viral membrane disruption. Conclusion Together, the findings in this study indicate that MCFA and GML inhibit ASFv in liquid conditions and that GML is also able to reduce ASFv infectivity in feed, which may help to curb disease transmission.

show abstract

Synthetic surfactin analogues have improved anti-PEDV properties

Cited by 45 publications

References 27 publications

Recent Advances in Biomedical, Therapeutic and Pharmaceutical Applications of Microbial Surfactants

Recent Advances in Biomedical, Therapeutic and Pharmaceutical Applications of Microbial Surfactants

Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity

Inhibition of African swine fever virus in liquid and feed by medium-chain fatty acids and glycerol monolaurate

Contact Info

Product

Resources

About